Specialty Pharma Journal Specialty, Precision & Technology
THOUSAND OAKS, Calif., Oct. 24, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that positive results from the Phase 3 SEAM-PsA study comparing the efficacy of Enbrel® (etanercept) monotherapy and ENBREL plus methotrexate to methotrexate monotherapy in patients with psoriatic arthritis (PsA) were presented in a late-breaking poster session at the 2018 American College of Rheumatology (ACR)/Association of …
Tag Archives: methotrexate
October, 2018
December, 2017
-
21 December
AbbVie’s Upadacitinib Meets All Primary and Secondary Endpoints in Late-Stage Rheumatoid Arthritis Study
NORTH CHICAGO, Ill., Dec. 20, 2017 /PRNewswire/ — AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-MONOTHERAPY clinical trial. This ongoing study evaluated upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, as a monotherapy treatment in patients with moderate to …
April, 2017
-
26 April
FDA Approves Silvergate’s XATMEP, the Only Ready-to-Use Methotrexate Oral Solution
DENVER, April 26, 2017 /PRNewswire/ — Silvergate Pharmaceuticals, Inc. (www.silvergatepharma.com), leaders in the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration (FDA) approved XATMEP (methotrexate) Oral Solution, the first and only FDA-approved methotrexate oral solution. XATMEP is indicated …
February, 2016
-
25 February
FDA Approves Pfizer’s Xeljanz XR for Treatment of Rheumatoid Arthritis
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved XELJANZ® XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily treatment of moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate (MTX). XELJANZ XR is the …